Academic Sponsors / Collaborators
Interaction Checker
We have produced various materials in PDF format to aid the use of experimental agents in the treatment of COVID-19.
These resources are freely available and the Liverpool Drug Interactions Group would like to encourage the dissemination (with an appropriate acknowledgement) of this drug-drug interaction information for non-commercial use. If referencing these Prescribing Resources, it is important to include the publication date since these resources are updated as new data come to light. Please cite as: [Prescribing Resource Title], [PDF Publication Date], University of Liverpool, available from www.covid19-druginteractions.org, [accession date].
UPDATED - Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added.
This document explains how we have evaluated the drug-drug interaction risk of the COVID-19 therapies (licensed and under clinical investigation) and gives details of their metabolism, interaction potential and cardiac effects.
Updated 17 January 2022
NEW - detailed recommendations for key COVID-19 therapies (including Paxlovid).
Details of the nature of drug interactions with key COVID-19 therapies and many comedication classes are given in this PDF.
Updated 20 January 2022
UPDATED – Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added.
A summary of interactions with COVID-19 antiviral therapies (licensed or under clinical investigation) and over 500 comedications are given in this PDF.
Updated 20 January 2022
UPDATED – Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added
A summary of interactions with COVID-19 host-directed therapies (licensed or under clinical investigation) and over 500 comedications are given in this PDF.
Updated 20 January 2022
UPDATED – Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added.
A summary of interactions with COVID-19 adjunct therapies and over 500 comedications are given in this PDF.
Updated 20 January 2022
UPDATED - Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added.
Advice for administering COVID-19 therapies (licensed or under clinical investigation) to patients who cannot swallow is given in this PDF.
Updated 17 January 2022
UPDATED - Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added.
Details of dose modifications for COVID-19 therapies (licensed or under clinical investigation) which may be required for patients with renal impairment are given in this PDF.
Updated 17 January 2022
UPDATED - Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added.
Details of dose modifications for COVID-19 therapies (licensed or under clinical investigation) which may be required for patients with hepatic impairment are given in this PDF.
Updated 17 January 2022
